Yong-Man Kim
Overview
Explore the profile of Yong-Man Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
2349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim S, Bae K, Lee J, Lee W, Ock C, Lee M, et al.
Cancer Med
. 2025 Feb;
14(4):e70576.
PMID: 39945311
Background: Venadaparib, a novel poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated high PARP-1/2 selectivity over other PARP family members and exhibited strong PARP-trapping activity, effectively inhibiting tumor growth in homologous...
2.
Kim J, Park S, Kim J, Lee S, Park J, Kim J, et al.
Gynecol Oncol
. 2025 Feb;
194:25-32.
PMID: 39923681
Objective: To evaluate the real-world efficacy and toxicity of olaparib maintenance therapy in Korean patients with BRCA-mutated ovarian cancer (OC), with an exploratory analysis of BRCA mutations. Methods: We conducted...
3.
Kim Y, Lee J, Park S, Kim Y, Park K, Kim Y
Gynecol Oncol
. 2025 Jan;
193:136-140.
PMID: 39864258
Objectives: To assess the predictive value of magnetic resonance imaging for vesicovaginal fistula development in cervical cancer patients with bladder invasion treated with definitive chemoradiotherapy. Methods: A retrospective review was...
4.
Lim M, Choi Y, Hur S, Kim Y, No J, Kim B, et al.
EClinicalMedicine
. 2025 Jan;
74():102716.
PMID: 39823099
Background: In an interim analysis of this phase 2 trial, adding the GX-188E vaccine to pembrolizumab resulted in manageable toxicity with antitumor activities in patients with recurrent or advanced cervical...
5.
Kim J, Park E, Lee S, Park J, Kim D, Suh D, et al.
Taiwan J Obstet Gynecol
. 2025 Jan;
64(1):61-67.
PMID: 39794053
Objective: To investigate the real-world efficacy and toxicity of paclitaxel-cisplatin-bevacizumab and identify prognostic factors for paclitaxel-cisplatin-bevacizumab in platinum-naïve primary stage IVB cervical cancer. Materials And Methods: We retrospectively reviewed patients...
6.
Min K, Kim N, Song J, Choi M, Lee S, Lee K, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410040
The Korean Gynecologic Oncology Group (KGOG) was established in 2002 and is the only organization in Korea conducting multi-center clinical trials for gynecologic cancers. Since its re-establishment as a non-profit...
7.
Lee J, Brady M, Miller A, Moore R, MacKay H, McNally L, et al.
J Clin Oncol
. 2024 Oct;
42(36):4305-4316.
PMID: 39361946
Purpose: We assessed the efficacy of cediranib, olaparib, and cediranib/olaparib compared with standard-of-care chemotherapy (SOC) in platinum-resistant or platinum-refractory epithelial ovarian cancer (PROC). Patients And Methods: NRG-GY005 is an open-label,...
8.
Yoo Y, Kim Y, Kim Y, Kim K, Jo U, Kim Y
Int J Gynecol Pathol
. 2024 Jun;
PMID: 38916173
The aim of this study was to investigate the pathologic prognostic factors such as tumor cell clusters (TCCs) in the fallopian tube lumen, myometrial invasion patterns, and positive peritoneal cytology...
9.
Salani R, McCormack M, Kim Y, Ghamande S, Hall S, Lorusso D, et al.
Int J Gynecol Cancer
. 2024 Jun;
34(8):1140-1148.
PMID: 38858106
Objective: To evaluate tiragolumab (anti-TIGIT) and atezolizumab (anti-PD-L1) as second- or third-line therapy for PD-L1-positive persistent/recurrent cervical cancer. Methods: In the open-label, non-comparative, randomized phase II SKYSCRAPER-04 trial (NCT04300647), patients...
10.
Kang S, Lee J, Kang O, Kim Y, Choi E, Lee S
Sci Rep
. 2024 May;
14(1):11894.
PMID: 38789484
Although immunotherapy has not yet been as successful in ovarian cancer (OC), it remains a potential therapeutic strategy. Preclinical models of OC are necessary to evaluate the efficacy of immuno-oncology...